Drug Profile

Interleukin 10 - TherapyX

Alternative Names: FAPXIL; IL-10NanoCap

Latest Information Update: 12 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator TherapyX
Class Anti-inflammatories; Antineoplastics; Interleukins
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Familial adenomatous polyposis
New Molecular Entity No

Highest Development Phases

Preclinical Familial adenomatous polyposis

Most Recent Events

21 Aug 2023 Preclinical trials in Familial adenomatous polyposis in USA (PO) prior to August 2023 (TherapyX pipeline, August 2023)
28 Nov 2022 No recent reports of development identified for research development in Familial-adenomatous-polyposis in USA (PO)
27 Oct 2018 Early research in Familial adenomatous polyposis in USA (PO) (TherapyX pipeline, October 2018)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com